Shares of Time Warner fell more than 2 percent on Wednesday on concerns that US President-elect Donald Trump will make good on his vow to block a proposed $85 billion acquisition by AT&T.
Trump said in October that the telecommunication company’s proposal to buy the owner of HBO, CNN and the Warner Bros film studio was an example of a “power structure” rigged against him and voters.
Time Warner shares were some 24.5 percent below the implied value of AT&T’s $107.50 per share cash-and-stock offer in early trading on Wednesday, compared to a just under 22 percent discount at Tuesday’s close, indicating greater investor skepticism that the companies will be able to complete the transaction.
Dealmakers said there will be an immediate slowdown in mergers and acquisitions as companies and advisers seek clues on how Trump’s antitrust enforcement policy will take shape and who he will choose to lead the Justice Department’s antitrust division and the Federal Trade Commission.
“I think a lot of deals will hit the pause button for a bit until we get some clarity on whether President Trump will moderate or be as disruptive as some expect,” said a senior Wall Street banker who asked not to be named because he was not authorized to speak with the media.
“It’s going to be a tough environment for everything until we see how [Trump] behaves as a leader,” the banker added.
Full Content: Investing
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Meta Begins Defense After FTC Concludes Case in Landmark Antitrust Trial
May 15, 2025 by
CPI
UK Data Bill Still No Closer to Passage As Parliamentary ‘Ping-Pong’ Drags On
May 15, 2025 by
CPI
Regeneron Pharmaceuticals Awarded $271.2M in Damages Against Amgen
May 15, 2025 by
CPI
FTC Chair Proposes 15% Staff Reduction Amid Budget Constraints
May 15, 2025 by
CPI
UK Urges Antitrust Watchdog to Prioritize Growth and Clarity in Business Regulation
May 15, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas